AlphAIAlphAI — Financial news for AI agents
theglobeandmail.comOCT 41 min read$MDT

RBC Capital Keeps Their Buy Rating on Medtronic (MDT)

RBC Capital's Kendall Au maintained a Buy rating on Medtronic (MDT) with a $118 price target. Medtronic closed at $86.44. Analyst consensus is Moderate Buy with a $103.41 target. Q2 revenue was $9.76B, up from $8.58B last year, with net profit at $1.47B, up from $1.04B.

Original reporting
theglobeandmail.com
Published Oct 4, 2026, 2:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 4, 2026, 3:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
RBC Capital Keeps Their Buy Rating on Medtronic (MDT) — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$MDTBullishLow
01

Why it matters

The reaffirmed Buy rating with a higher price target could nudge the stock modestly higher, but no new catalyst is introduced.

02

Market read

Limited relevance; primarily an analyst opinion piece with modest bullish bias.

03

What to watch

Potential competitive pressures from other med‑tech firms and upcoming regulatory reviews.

Relevance 4/10Novelty 2/10Timing: today

Background

Analyst coverage update following Medtronic's recent quarterly earnings release.

Company-level read

Ticker impact

$MDTBullishMedium confidence
Context

RBC Capital maintained a Buy rating on Medtronic with a $118 price target, citing its recent earnings beat.

Expected impact

potential modest upside as target exceeds current price

Evidence & confidence

The rating upgrade is a repeat action; investors may view the higher target as a slight bullish signal.

Market effects

Sector

Reinforces positive sentiment in the healthcare equipment sector.

Regional

Limited to U.S. markets where Medtronic trades.

Global

Minimal global impact beyond Medtronic's investor base.

Counterpoint

What could challenge this read

The rating maintenance may be seen as a lack of new catalyst, limiting upside.

Key entities

  • Company
    Medtronic

    Medical device manufacturer (ticker MDT).

  • Analyst
    RBC Capital

    Equity research firm covering healthcare.

Read at source← All news

Related articles

OCT 7
$MDTHighAI 8/10

Medtronic Sets MiniMed Split-Off Exchange Ratio at 4.5939 Upper Limit

Medtronic (MDT) set the final exchange ratio for its split-off of MiniMed (MMED) at 4.5939 shares of MMED for each MDT share. The ratio is at the offer's upper limit, valuing MDT shares at 100% and MMED at 93% of their average prices. The offer expires October 9, 2026, and may be oversubscribed, with proration possible. The exchange is expected to be tax-free for U.S. federal income tax purposes.

securities.io2 min
OCT 7
$MDTHighAI 8/10

Medtronic sets final exchange ratio for MiniMed split-off

Medtronic (NYSE:MDT) set the final exchange ratio for its offer to swap shares for MiniMed (NASDAQ:MMED) stock at 4.5939. The company will exchange up to 225,361,295 MiniMed shares. If oversubscribed, Medtronic may exchange additional shares without extending the offer. The exchange offer expires at midnight on Friday.

investing.com2 min
OCT 7
$MDTMed

Medtronic (MDT) Could Be 24% Undervalued As CPT Code Wins Support Growth

Medtronic (MDT) received permanent CPT codes for its Altaviva and Symplicity Spyral devices. Shares are down 7.52% in 1 month and 9.33% YTD, but up 26.12% over 3 years. Analysts estimate MDT is 24.5% undervalued with a fair value of $115.38 vs. last close at $87.09. Management hinted at higher growth aspirations, to be detailed in December.

simplywall.st2 min